VIA Pharmaceuticals Inc. (VIAP) Financials Nov 13,
Post# of 250675
Posted On: 11/17/2014 5:06:31 AM
VIA Pharmaceuticals Inc. (VIAP) Financials Nov 13, 2014, 12:00 a.m.
Income Statement Balance Sheet Cash Flow Statement
Annual Financials for VIA Pharmaceuticals Inc.
Fiscal year is January-December. All values USD millions. 2006 2007 2008 2009 2010 5-year trend
Sales/Revenue 83,333 0 0 0 0
Cost of Goods Sold (COGS) incl. D&A 61,785 119,286 205,919 136,360 74,882
COGS excluding D&A 0 0 0 0 0
Depreciation & Amortization Expense 61,785 119,286 205,919 136,360 74,882
Depreciation 61,785 117,985 183,602 - 74,882
Amortization of Intangibles - 1,301 22,317 - -
Gross Income 21,548 (119,286) (205,919) (136,360) (74,882)
2006 2007 2008 2009 2010 5-year trend
SG&A Expense 15.77M 18.41M 20.26M 13.12M 5.84M
Research & Development 9.61M 10.63M 11.75M 6.03M 1.66M
Other SG&A 6.15M 7.77M 8.51M 7.08M 4.18M
Other Operating Expense 0 0 0 - 0
Unusual Expense 92,843 3.82M 0 0 106,959
EBIT after Unusual Expense (92,843) (3.82M) 0 0 (106,959)
Non Operating Income/Expense 0 (14,375) 2,764 8,601 (17,891)
Non-Operating Interest Income 976,516 588,174 189,656 - 0
Equity in Affiliates (Pretax) 0 0 0 0 0
Interest Expense 497,860 60,193 6,029 7.73M 3.56M
Gross Interest Expense 497,860 60,193 6,029 7.73M 3.56M
Interest Capitalized 0 0 0 - 0
Pretax Income (15.36M) (21.84M) (20.27M) (20.98M) (9.6M)
Income Tax 0 0 0 0 0
Income Tax - Current Domestic 0 0 0 - 0
Income Tax - Current Foreign 0 0 0 - 0
Income Tax - Deferred Domestic 0 0 0 - 0
Income Tax - Deferred Foreign 0 0 0 - 0
Income Tax Credits 0 0 0 - 0
Equity in Affiliates 0 0 0 0 0
Other After Tax Income (Expense) 0 0 0 - 0
Consolidated Net Income (15.36M) (21.84M) (20.27M) (20.98M) (9.6M)
Minority Interest Expense 0 0 0 0 0
Net Income (15.36M) (21.84M) (20.27M) (20.98M) (9.6M)
Extraordinaries & Discontinued Operations 0 0 0 0 0
Extra Items & Gain/Loss Sale Of Assets 0 0 0 0 0
Cumulative Effect - Accounting Chg 0 0 0 - 0
Discontinued Operations 0 0 0 0 0
Net Income After Extraordinaries (15.36M) (21.84M) (20.27M) (20.98M) (9.6M)
Preferred Dividends 498,350 0 0 0 0
Net Income Available to Common (15.86M) (21.84M) (20.27M) (20.98M) (9.6M)
EPS (Basic) (12.00) (2.24) (1.03) (1.05) (0.47)
Basic Shares Outstanding 1.31M 9.73M 19.61M 19.94M 20.4M
EPS (Diluted) (12.00) (2.24) (1.03) (1.05) (0.47)
Diluted Shares Outstanding 1.31M 9.73M 19.61M 19.94M 20.4M
EBITDA (15.68M) (18.41M) (20.26M) (13.12M) (5.84M)
Copyright 2014 FactSet Research Systems Inc. All rights reserved. Source FactSet Fundamentals.
Income Statement Balance Sheet Cash Flow Statement
Annual Financials for VIA Pharmaceuticals Inc.
Fiscal year is January-December. All values USD millions. 2006 2007 2008 2009 2010 5-year trend
Sales/Revenue 83,333 0 0 0 0
Cost of Goods Sold (COGS) incl. D&A 61,785 119,286 205,919 136,360 74,882
COGS excluding D&A 0 0 0 0 0
Depreciation & Amortization Expense 61,785 119,286 205,919 136,360 74,882
Depreciation 61,785 117,985 183,602 - 74,882
Amortization of Intangibles - 1,301 22,317 - -
Gross Income 21,548 (119,286) (205,919) (136,360) (74,882)
2006 2007 2008 2009 2010 5-year trend
SG&A Expense 15.77M 18.41M 20.26M 13.12M 5.84M
Research & Development 9.61M 10.63M 11.75M 6.03M 1.66M
Other SG&A 6.15M 7.77M 8.51M 7.08M 4.18M
Other Operating Expense 0 0 0 - 0
Unusual Expense 92,843 3.82M 0 0 106,959
EBIT after Unusual Expense (92,843) (3.82M) 0 0 (106,959)
Non Operating Income/Expense 0 (14,375) 2,764 8,601 (17,891)
Non-Operating Interest Income 976,516 588,174 189,656 - 0
Equity in Affiliates (Pretax) 0 0 0 0 0
Interest Expense 497,860 60,193 6,029 7.73M 3.56M
Gross Interest Expense 497,860 60,193 6,029 7.73M 3.56M
Interest Capitalized 0 0 0 - 0
Pretax Income (15.36M) (21.84M) (20.27M) (20.98M) (9.6M)
Income Tax 0 0 0 0 0
Income Tax - Current Domestic 0 0 0 - 0
Income Tax - Current Foreign 0 0 0 - 0
Income Tax - Deferred Domestic 0 0 0 - 0
Income Tax - Deferred Foreign 0 0 0 - 0
Income Tax Credits 0 0 0 - 0
Equity in Affiliates 0 0 0 0 0
Other After Tax Income (Expense) 0 0 0 - 0
Consolidated Net Income (15.36M) (21.84M) (20.27M) (20.98M) (9.6M)
Minority Interest Expense 0 0 0 0 0
Net Income (15.36M) (21.84M) (20.27M) (20.98M) (9.6M)
Extraordinaries & Discontinued Operations 0 0 0 0 0
Extra Items & Gain/Loss Sale Of Assets 0 0 0 0 0
Cumulative Effect - Accounting Chg 0 0 0 - 0
Discontinued Operations 0 0 0 0 0
Net Income After Extraordinaries (15.36M) (21.84M) (20.27M) (20.98M) (9.6M)
Preferred Dividends 498,350 0 0 0 0
Net Income Available to Common (15.86M) (21.84M) (20.27M) (20.98M) (9.6M)
EPS (Basic) (12.00) (2.24) (1.03) (1.05) (0.47)
Basic Shares Outstanding 1.31M 9.73M 19.61M 19.94M 20.4M
EPS (Diluted) (12.00) (2.24) (1.03) (1.05) (0.47)
Diluted Shares Outstanding 1.31M 9.73M 19.61M 19.94M 20.4M
EBITDA (15.68M) (18.41M) (20.26M) (13.12M) (5.84M)
Copyright 2014 FactSet Research Systems Inc. All rights reserved. Source FactSet Fundamentals.
(0)
(0)